Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01511172
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
  • metformin — DRUG
    1000 mg daily, administered orally
  • placebo — DRUG
    Metformin placebo administered orally. 1000 mg daily
  • placebo — DRUG
    NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
  • glimepiride — DRUG
    Individually adjusted dose, administered orally

Study Details

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effect on glycemic control of NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone in subjects with type 2 diabetes previously treated with OHAs (oral hypoglycaemic agents).

Key Dates

Start date
Aug 31, 2002
Status verified
Jan 2017
Primary completion
Dec 31, 2002
Completion
Dec 31, 2002

Study Design

Enrollment
145 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC 90-1170 + Met
  • Experimental: NNC 90-1170 + Met placebo
  • Placebo Comparator: Met + NNC 90-1170 placebo
  • Active Comparator: Met + Glim

Primary Outcome Measure

Fasting plasma/serum glucose

Related Studies